In silico prediction of substrate properties for ABC-multidrug transporters

Overexpression of ABC (ATP-binding cassette)-type drug efflux pumps, such as ABCB1, ABCC1 and ABCG2 in cancer cells confers multi-drug resistance (MDR) and represents a major cause of treatment failures in cancer therapy. Furthermore, there is increasing evidence for the important contribution of ABC-transporters to bioavailability, distribution, elimination and blood–brain barrier permeation of drug candidates. This review presents an overview on the different computational methods and models pursued to predict ABC-transporter substrate properties of drug-like compounds. They range from linear discriminant analysis to pharmacophore modelling and machine learning algorithms. Many of these models show a satisfying performance within the study-specific, defined chemical space but general applicability for the whole drug-like chemical space still needs to be proven. First attempts aiming towards selectivity profiling for ligands of the two polyspecific transporters ABCB1 and ABCG2 is also discussed. This might pave the way for a pharmacological profiling of compound series with special focus on their ADMET (absorption, distribution, metabolism, excretion and toxicity) properties.

[1]  L. Doyle,et al.  Mining our ABCs: pharmacogenomic approach for evaluating transporter function in cancer drug resistance. , 2004, Cancer cell.

[2]  J. Polli,et al.  Rational use of in vitro P-glycoprotein assays in drug discovery. , 2001, The Journal of pharmacology and experimental therapeutics.

[3]  P. Coleman,et al.  Kinesin spindle protein (KSP) inhibitors. Part V: discovery of 2-propylamino-2,4-diaryl-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by beta-fluorination to overcome cellular efflux by P-glycoprotein. , 2007, Bioorganic & medicinal chemistry letters.

[4]  W. T. Beck,et al.  Structural characteristics of compounds that modulate P-glycoprotein-associated multidrug resistance. , 1990, Advances in enzyme regulation.

[5]  G. Ecker,et al.  Lead Identification for Modulators of Multidrug Resistance based on in silico Screening with a Pharmacophoric Feature Model , 2004, Archiv der Pharmazie.

[6]  Geoffrey Chang,et al.  Structure of MsbA from Vibrio cholera: a multidrug resistance ABC transporter homolog in a closed conformation. , 2003, Journal of molecular biology.

[7]  F. Loor,et al.  Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. , 1996, Anti-cancer drugs.

[8]  R. Dawson,et al.  Structure of a bacterial multidrug ABC transporter , 2006, Nature.

[9]  Thierry Langer,et al.  Molecule-pharmacophore superpositioning and pattern matching in computational drug design. , 2008, Drug discovery today.

[10]  Roy J. Vaz,et al.  Antitargets : prediction and prevention of drug side effects , 2008 .

[11]  Stephan Kopp,et al.  Similarity based SAR (SIBAR) as tool for early ADME profiling , 2002, J. Comput. Aided Mol. Des..

[12]  Scott Boyer,et al.  Ligand-Based Approach to in Silico Pharmacology: Nuclear Receptor Profiling. , 2007 .

[13]  G Ecker,et al.  Structure-activity relationship studies of propafenone analogs based on P-glycoprotein ATPase activity measurements. , 1999, Biochemical pharmacology.

[14]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[15]  Ying Sun,et al.  Design, synthesis, cytoselective toxicity, structure-activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells. , 2008, Journal of medicinal chemistry.

[16]  A. Schinkel,et al.  Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. , 2003, Advanced drug delivery reviews.

[17]  S. Ekins,et al.  Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. , 1999, The Journal of pharmacology and experimental therapeutics.

[18]  R. Fine,et al.  Tamoxifen aziridine, a novel affinity probe for P-glycoprotein in multidrug resistant cells. , 1994, Biochemical and biophysical research communications.

[19]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[20]  X. Ling,et al.  Significance Analysis and Multiple Pharmacophore Models for Differentiating P-Glycoprotein Substrates. , 2008 .

[21]  S. Ekins,et al.  Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors. , 1999, The Journal of pharmacology and experimental therapeutics.

[22]  Xuefeng Bruce Ling,et al.  Significance Analysis and Multiple Pharmacophore Models for Differentiating P-Glycoprotein Substrates , 2007, J. Chem. Inf. Model..

[23]  Stephan Kopp,et al.  Multispecificity of Drug Transporters: Probing Inhibitor Selectivity for the Human Drug Efflux Transporters ABCB1 and ABCG2 , 2007, ChemMedChem.

[24]  A. Ravna,et al.  Molecular model of the outward facing state of the human P-glycoprotein (ABCB1), and comparison to a model of the human MRP5 (ABCC5) , 2007, Theoretical Biology & Medical Modelling.

[25]  Ling Yang,et al.  Classification of Substrates and Inhibitors of P-Glycoprotein Using Unsupervised Machine Learning Approach , 2005, J. Chem. Inf. Model..

[26]  Jordi Mestres,et al.  SHED: Shannon Entropy Descriptors from Topological Feature Distributions , 2006, J. Chem. Inf. Model..

[27]  S. Z. Imam,et al.  Medicinal importance of grapefruit juice and its interaction with various drugs , 2007, Nutrition journal.

[28]  A. Seelig,et al.  Structure-activity relationship of P-glycoprotein substrates and modifiers. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[29]  Xin Chen,et al.  Effect of Molecular Descriptor Feature Selection in Support Vector Machine Classification of Pharmacokinetic and Toxicological Properties of Chemical Agents , 2004, J. Chem. Inf. Model..

[30]  K. K. Nanda,et al.  Potent antagonists of the Kv1.5 potassium channel: synthesis and evaluation of analogous N,N-diisopropyl-2-(pyridine-3-yl)acetamides. , 2006, Bioorganic & medicinal chemistry letters.

[31]  O. van Tellingen.  The importance of drug-transporting P-glycoproteins in toxicology. , 2001, Toxicology letters.

[32]  Garland R. Marshall,et al.  Chapter 28. Pharmacophore Identification and Receptor Mapping , 1980 .

[33]  Remigijus Didziapetris,et al.  Classification Analysis of P-Glycoprotein Substrate Specificity , 2003, Journal of drug targeting.

[34]  B Testa,et al.  In silico pharmacology for drug discovery: applications to targets and beyond , 2007, British journal of pharmacology.

[35]  M. Gleeson.  Generation of a set of simple, interpretable ADMET rules of thumb. , 2008, Journal of medicinal chemistry.

[36]  G Ecker,et al.  The importance of a nitrogen atom in modulators of multidrug resistance. , 1999, Molecular pharmacology.

[37]  Vijay K Gombar,et al.  Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model. , 2004, Journal of pharmaceutical sciences.

[38]  Marc Adenot,et al.  Blood-Brain Barrier Permeation Models: Discriminating between Potential CNS and Non-CNS Drugs Including P-Glycoprotein Substrates , 2004, J. Chem. Inf. Model..

[39]  Miguel A. Cabrera,et al.  A topological substructural approach for the prediction of P-glycoprotein substrates. , 2006, Journal of pharmaceutical sciences.

[40]  A. Mitra,et al.  MDR- and CYP3A4-Mediated Drug–Drug Interactions , 2006, Journal of Neuroimmune Pharmacology.

[41]  Sean Ekins,et al.  Pharmacophore-based discovery of ligands for drug transporters. , 2006, Advanced drug delivery reviews.

[42]  Bo Feng,et al.  In Vitro P-glycoprotein Assays to Predict the in Vivo Interactions of P-glycoprotein with Drugs in the Central Nervous System , 2008, Drug Metabolism and Disposition.

[43]  A. Ravna,et al.  A molecular model of a putative substrate releasing conformation of multidrug resistance protein 5 (MRP5). , 2008, European journal of medicinal chemistry.

[44]  J. F. Wang,et al.  Prediction of P-Glycoprotein Substrates by a Support Vector Machine Approach , 2004, J. Chem. Inf. Model..

[45]  Alexander Golbraikh,et al.  Combinatorial QSAR Modeling of P-Glycoprotein Substrates , 2006, J. Chem. Inf. Model..

[46]  J. H. Beijnen,et al.  Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs , 1994, Cell.

[47]  Gabriele Cruciani,et al.  A pharmacophore hypothesis for P-glycoprotein substrate recognition using GRIND-based 3D-QSAR. , 2005, Journal of medicinal chemistry.

[48]  C. B. Roth,et al.  Structure of MsbA from E. coli: a homolog of the multidrug resistance ATP binding cassette (ABC) transporters. , 2001, Science.

[49]  Erik Evensen,et al.  A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein. , 2002, Journal of medicinal chemistry.

[50]  G. Ecker,et al.  In silico prediction of substrate properties for ABC-multidrug transporters. , 2008, Expert Opinion on Drug Metabolism & Toxicology.

[51]  E. Hazai,et al.  Homology modeling of breast cancer resistance protein (ABCG2). , 2008, Journal of structural biology.

[52]  H L Pearce,et al.  Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[53]  R. Arceci,et al.  P-glycoprotein mediates profound resistance to bisantrene. , 1994, Oncology research.

[54]  M C Willingham,et al.  Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Geoffrey Chang,et al.  Flexibility in the ABC transporter MsbA: Alternating access with a twist , 2007, Proceedings of the National Academy of Sciences.

[56]  M. Gottesman,et al.  Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.

[57]  John N Weinstein,et al.  Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. , 2004, Cancer cell.

[58]  A. Seelig.  A general pattern for substrate recognition by P-glycoprotein. , 1998, European journal of biochemistry.

[59]  P. Meier,et al.  Hepatobiliary transporters and drug‐induced cholestasis , 2006, Hepatology.

[60]  M. Delaforge,et al.  Characterization of two pharmacophores on the multidrug transporter P-glycoprotein. , 2002, Molecular pharmacology.

[61]  Praveen M. Bahadduri,et al.  Rapid Identification of P-glycoprotein Substrates and Inhibitors , 2006, Drug Metabolism and Disposition.

[62]  S. Ekins,et al.  In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling , 2007, British journal of pharmacology.

[63]  I. Pajeva,et al.  Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis). , 2002, Journal of medicinal chemistry.

[64]  Leslie Z. Benet,et al.  Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System , 2004, Pharmaceutical Research.

[65]  K. Locher,et al.  Structure of the multidrug ABC transporter Sav1866 from Staphylococcus aureus in complex with AMP‐PNP , 2007, FEBS letters.

[66]  G. V. Paolini,et al.  Global mapping of pharmacological space , 2006, Nature Biotechnology.

[67]  Yiyu Cheng,et al.  Identifying P-Glycoprotein Substrates Using a Support Vector Machine Optimized by a Particle Swarm , 2007, J. Chem. Inf. Model..

[68]  S. Ekins,et al.  Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. , 2002, Molecular pharmacology.

[69]  L. Mir,et al.  Absence of cooperativity for MgATP and verapamil effects on the ATPase activity of P-glycoprotein containing membrane vesicles. , 1993, Biochemical and biophysical research communications.

[70]  Thomas J. Raub,et al.  P-glycoprotein recognition of substrates and circumvention through rational drug design. , 2006, Molecular pharmaceutics.

[71]  G Klopman,et al.  Quantitative structure-activity relationship of multidrug resistance reversal agents. , 1997, Molecular pharmacology.

[72]  Barbara Zdrazil,et al.  Similarity‐Based Descriptors (SIBAR) as Tool for QSAR Studies on P‐Glycoprotein Inhibitors: Influence of the Reference Set , 2007 .

[73]  E. Schuetz,et al.  Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. , 1996, Molecular pharmacology.

[74]  J. Hochman,et al.  Evaluation of drug interactions with P-glycoprotein in drug discovery: in vitro assessment of the potential for drug-drug interactions with P-glycoprotein. , 2002, Current drug metabolism.

[75]  S. Ekins,et al.  Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. , 2002, Molecular pharmacology.